echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Lancet oncol: Tafasitamab combined to the efficacy of nadoamine treatment for relapse/refractive diffuse large B cell lymphoma

    Lancet oncol: Tafasitamab combined to the efficacy of nadoamine treatment for relapse/refractive diffuse large B cell lymphoma

    • Last Update: 2020-06-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    Relapsed or refractive diffuse large B-cell lymphoma is not suitable for patients with self-contained stem cell transplantation with poor prognosis and few treatment optionsTafasitamab (MOR208) is a Fc-enhanced human-derived anti-CD19 monoclonal antibody that shows preclinical and monodrugic activity in patients with recurrent or refractive B-cell malignanciesPreclinical data suggest that tafasitamab may have synergies with indomineThe purpose of this study was to assess the anti-tumor activity and safety of tafasitamab in patients with recurrent or refractive diffuse large B-cell lymphoma patients who were not suitable for kineditoid stem cell transplantationThis study is a multi-center edgy single-arm phase 2 trial (L-MIND) that recruited 81 hethography diagnoses from January 18, 2016 to November 15, 2017 that are not suitable for relapse or refractive diffuse sepsis of self-contained stem cell transplants or high doses of chemotherapy Patients with large B-cell lymphoma were treated with tafasitamab (12 mg/kg, still drops) and reinamine (25 mg/day, oral) for 12 courses of treatment (28 days/course), followed by tafasitamab monomedicine to maintain treatment until the course progressesThe main endpoint is the objective mitigation rateOf the 81 patients recruited, 80 received at least one dose of tafasitamab and renadomineAs of November 30, 2018, the median follow-up was 13.2 months (IQR 7.3-20.4)48 (48/80, 60%) patients received objective remission: 34 (43%) received full remission, and 14 (18%) received partial remissionThe most common adverse reactions of 3-4 were neusconotyte reduction (39/81, 48%), platelet reduction (17%) and feveriatly neutrophils (12%)Severe adverse reactions occurred in 41 (51%) patientsThe most common severe adverse reactions were pneumonia (6%), decreased febrile neutrophils (6%), pulmonary embolism (4%), bronchitis (2%), atrial fibrillation (2%) and congestive heart failure (2%)Tafasitamab combined with nadoamine is well tolerated in patients with recurrent or refractable diffuse large B-cell lymphoma that is not suitable for an autonomous stem cell transplant, and can be treated with a higher percentage of complete remission, or can be a new option for such patients
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.